Fig. 6: Ultrasound responsive chemotherapeutics sensitized checkpoint inhibitors on animals with MC38 bilateral tumors.

a C57BL/6 mice were subcutaneously injected with 500,000 MC38 cells on the right flank (primary tumor) and 250,000 MC38 cells on the left flank (distant tumor) on day 0. On days 10 and 13, tumor-bearing mice were i.v. injected with LID (DOX 0.5 mg/kg, ICG 4 mg/kg) or control formulations. On days 11 and 14, ultrasound (2 W/cm², 50%, 1 MHz, 5 min) was applied to the primary tumor for indicated groups (the distant tumor was not exposed to ultrasound). On days 10, 13, and 16, the PD-L1 antibody (75 μg/dose) was i.p. injected for indicated groups. b, c The average and individual tumor growth curves for primary tumors (exposed to ultrasound) (n = 8 mice per group). d, e The average and individual tumor growth curves for distant tumors (not exposed to ultrasound) (n = 8 mice per group). CR = complete regression. f, g Percent of CD8 + T cells among CD3 + T cells in the primary tumor on day 18 post tumor inoculation. h, i Percent of CD8 + T cells among CD3 + T cells in the distant tumor on day 18 post tumor inoculation (n = 3). The data represent mean ± SEM (b, d, g, i). Data were analyzed by one-way ANOVA (g, i) or two-way ANOVA (b, d) with Tukey’s multiple comparisons post test. Source data are provided as a Source Data file.